Lilly adding two more insulin options to discount program
Under fire over insulin prices, the Indianapolis-based drugmaker said Tuesday morning it is introducing lower-priced versions of its Humalog KwikPen and Humalog Junior KwikPen.
Diabetes
Articles
Lilly launches awareness campaign for insulin discount options
Under fire from politicians, patients and health care advocates over the price of insulin, Eli Lilly and Co. announced a campaign Thursday morning to raise awareness of cost-saving options for the drug.
Lilly begins selling half-price version of popular Humalog insulin
The fast-acting insulin, which diabetics inject shortly before each meal, is used by about 700,000 Americans.
Harvard study involving Anthem unit finds older insulins are both safe, cheaper
Increasingly, top researchers are questioning whether drugs such as Lantus from Sanofi, Levemir and Novolog from Novo Nordisk A/S, and Humalog from Eli Lilly and Co. are really needed for many patients.
Hunger, food insecurity continue to vex Indiana residents
In Indiana, one million people face food insecurity, and in Indianapolis the number is approaching nearly 175,000—or more than 18 percent of the population.
Lilly might market diabetes drug for obesity after research results
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
Roche using data-driven diagnostic tools to reshape patient care
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
Q&A: What’s behind the growing scrutiny of insulin prices?
The American Medical Association recently called on regulators to monitor competition among the three drugmakers who control the market—Indianapolis-based Eli Lilly and Co., Denmark-based Novo Nordisk and Paris-based Sanofi.
Crawfordsville startup CorVus fattens pigs for science
The newly built farm uses a high-fat, high-cholesterol diet to give animals heart disease and diabetes to help medical researchers find treatments.
Major health initiative targets 3 Indianapolis neighborhoods with high diabetes rates
A five-year, $7 million program is led and supported by a coalition of local health institutions, including Eli Lilly and Co., Fairbanks School of Public Health and Eskenazi Health. It is based on a model that Lilly has used in other countries.
IndyGo’s daunting task: Turn drivers into health fanatics
Since starting a wellness program in 2010, IndyGo has seen employee participation climb from just a few, skeptical workers to 97 percent of the workforce.
Roche’s struggling diabetes unit looks toward ‘monster’ for boost
Roche Holding AG—the Basel, Switzerland-based parent of Indianapolis-based Roche Diagnostics—has enlisted a little green gremlin to help rescue its diabetes business after a decade of declining sales.
Lawsuit accuses Lilly of using kickbacks to boost insulin sales
A recently unsealed suit accuses the Indianapolis-based drugmaker of offering free nursing services to doctors to induce them to prescribe the company’s products.
Food insecurity, hunger vex large swath of Indianapolis residents
Nearly 175,000 food-insecure people live in the city. About 47,000 of them are children, whose ability to learn and thrive can be hampered, according to panelists at a local hunger summit on Friday.
Lilly insulin prices come under microscope
Over the past 20 years, while the price of a gallon of milk climbed 23 percent and the sticker on a Dodge Caravan minivan rose 21 percent, the list price of the insulin Humalog shot up 1,157 percent.
Lilly, other drug giants hunt for patients in India’s remote corners
Global pharmaceutical companies including Indianapolis-based Eli Lilly and Co. are heading into smaller cities and rural areas to learn about the health care needs of about 70 percent of India’s population.
Roche hoping to gain edge with new diabetes-testing product
Roche Group is rolling out a new blood-glucose meter and a savings program for test strips, which it says it will make diabetes care more affordable.
Lilly diabetes drug Jardiance falls short of quarterly sales predictions
Shares in Eli Lilly and Co. stock fell more than 3 percent Tuesday after the Indianapolis-based drugmaker released a quarterly earnings report that showed sales of potential blockbuster drug Jardiance missed expectations by a wide margin.
Local Roche units sue pharmacies over alleged test-strip scheme
Two Indianapolis-based subsidiaries of Swiss pharmaceutical giant Roche Group are accusing a group of pharmacies and supply houses of engaging in an elaborate scheme to defraud Roche of millions of dollars worth of sales on diabetes test strips.
UPDATE: Lilly to invest $85M in Indy as part of diabetes expansion
The expansion at the Lilly Technology Center southwest of downtown is part of an $850 million investment the company is making this year in its U.S. research labs, manufacturing plants and other operations.